Trials / Completed
CompletedNCT00453440
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701
Prospective Epidemiological Study of the Prevalence of HLA-B*5701 in HIV-1 Infected UK Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,502 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to determine the prevalence of a genetic marker, HLA-B5701, in the UK population. HLA-B\*5701 has been strongly associated with the risk of an allergic reaction to a HIV medicine, Abacavir. The allergic reaction is known as a hypersensitivity reaction. The study is a prospective study inviting HIV-1 positive patients over the age of 18 years to participate. Each participant will complete one study visit. They will be asked for details of their background including their age, sex, ethnicity, country of origin and parental country of origin. They will be asked to give two samples to test for the presence of the genetic marker HLA-B\*5701. The two samples are: * A cheek swab * A blood sample In selected centres patients may be asked to provide up to two additional blood samples. These samples will be used to help develop and validate new methods of determining HLA-B\*5701 testing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Cheek swab & blood test | Cheek swab \& blood test |
Timeline
- Start date
- 2007-03-20
- Primary completion
- 2007-08-10
- Completion
- 2007-08-10
- First posted
- 2007-03-29
- Last updated
- 2017-09-12
Locations
8 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00453440. Inclusion in this directory is not an endorsement.